Cargando…
Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides
Pancreatic neuroendocrine tumours (pNETs) secreting proglucagon are associated with phenotypic heterogeneity. Here, we describe two patients with pNETs and varied clinical phenotypes due to differential processing and secretion of proglucagon-derived peptides (PGDPs). Case 1, a 57-year-old woman pre...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685488/ https://www.ncbi.nlm.nih.gov/pubmed/26693280 http://dx.doi.org/10.1530/EDM-15-0105 |
_version_ | 1782406325494349824 |
---|---|
author | Challis, Benjamin G Albrechtsen, Nicolai J Wewer Bansiya, Vishakha Burling, Keith Barker, Peter Hartmann, Bolette Gribble, Fiona O'Rahilly, Stephen Holst, Jens J Simpson, Helen L |
author_facet | Challis, Benjamin G Albrechtsen, Nicolai J Wewer Bansiya, Vishakha Burling, Keith Barker, Peter Hartmann, Bolette Gribble, Fiona O'Rahilly, Stephen Holst, Jens J Simpson, Helen L |
author_sort | Challis, Benjamin G |
collection | PubMed |
description | Pancreatic neuroendocrine tumours (pNETs) secreting proglucagon are associated with phenotypic heterogeneity. Here, we describe two patients with pNETs and varied clinical phenotypes due to differential processing and secretion of proglucagon-derived peptides (PGDPs). Case 1, a 57-year-old woman presented with necrolytic migratory erythema, anorexia, constipation and hyperinsulinaemic hypoglycaemia. She was found to have a grade 1 pNET, small bowel mucosal thickening and hyperglucagonaemia. Somatostatin analogue (SSA) therapy improved appetite, abolished hypoglycaemia and improved the rash. Case 2, a 48-year-old male presented with diabetes mellitus, diarrhoea, weight loss, nausea, vomiting and perineal rash due to a grade 1 metastatic pNET and hyperglucagonaemia. In both cases, plasma levels of all measured PGDPs were elevated and attenuated following SSA therapy. In case 1, there was increased production of intact glucagon-like peptide 1 (GLP-1) and GLP-2, similar to that of the enteroendocrine L cell. In case 2, pancreatic glucagon was elevated due to a pancreatic α-cell-like proglucagon processing profile. In summary, we describe two patients with pNETs and heterogeneous clinical phenotypes due to differential processing and secretion of PGDPs. This is the first description of a patient with symptomatic hyperinsulinaemic hypoglycaemia and marked gastrointestinal dysfunction due to, in part, a proglucagon-expressing pNET. LEARNING POINTS: PGDPs exhibit a diverse range of biological activities including critical roles in glucose and amino acid metabolism, energy homeostasis and gastrointestinal physiology. The clinical manifestations of proglucagon-expressing tumours may exhibit marked phenotypic variation due to the biochemical heterogeneity of their secreted peptide repertoire. Specific and precise biochemical assessment of individuals with proglucagon-expressing tumours may provide opportunities for improved diagnosis and clinical management. |
format | Online Article Text |
id | pubmed-4685488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-46854882015-12-21 Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides Challis, Benjamin G Albrechtsen, Nicolai J Wewer Bansiya, Vishakha Burling, Keith Barker, Peter Hartmann, Bolette Gribble, Fiona O'Rahilly, Stephen Holst, Jens J Simpson, Helen L Endocrinol Diabetes Metab Case Rep Insight into Disease Pathogenesis or Mechanism of Therapy Pancreatic neuroendocrine tumours (pNETs) secreting proglucagon are associated with phenotypic heterogeneity. Here, we describe two patients with pNETs and varied clinical phenotypes due to differential processing and secretion of proglucagon-derived peptides (PGDPs). Case 1, a 57-year-old woman presented with necrolytic migratory erythema, anorexia, constipation and hyperinsulinaemic hypoglycaemia. She was found to have a grade 1 pNET, small bowel mucosal thickening and hyperglucagonaemia. Somatostatin analogue (SSA) therapy improved appetite, abolished hypoglycaemia and improved the rash. Case 2, a 48-year-old male presented with diabetes mellitus, diarrhoea, weight loss, nausea, vomiting and perineal rash due to a grade 1 metastatic pNET and hyperglucagonaemia. In both cases, plasma levels of all measured PGDPs were elevated and attenuated following SSA therapy. In case 1, there was increased production of intact glucagon-like peptide 1 (GLP-1) and GLP-2, similar to that of the enteroendocrine L cell. In case 2, pancreatic glucagon was elevated due to a pancreatic α-cell-like proglucagon processing profile. In summary, we describe two patients with pNETs and heterogeneous clinical phenotypes due to differential processing and secretion of PGDPs. This is the first description of a patient with symptomatic hyperinsulinaemic hypoglycaemia and marked gastrointestinal dysfunction due to, in part, a proglucagon-expressing pNET. LEARNING POINTS: PGDPs exhibit a diverse range of biological activities including critical roles in glucose and amino acid metabolism, energy homeostasis and gastrointestinal physiology. The clinical manifestations of proglucagon-expressing tumours may exhibit marked phenotypic variation due to the biochemical heterogeneity of their secreted peptide repertoire. Specific and precise biochemical assessment of individuals with proglucagon-expressing tumours may provide opportunities for improved diagnosis and clinical management. Bioscientifica Ltd 2015-12-01 2015 /pmc/articles/PMC4685488/ /pubmed/26693280 http://dx.doi.org/10.1530/EDM-15-0105 Text en © 2015 The authors This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB) . |
spellingShingle | Insight into Disease Pathogenesis or Mechanism of Therapy Challis, Benjamin G Albrechtsen, Nicolai J Wewer Bansiya, Vishakha Burling, Keith Barker, Peter Hartmann, Bolette Gribble, Fiona O'Rahilly, Stephen Holst, Jens J Simpson, Helen L Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides |
title | Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides |
title_full | Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides |
title_fullStr | Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides |
title_full_unstemmed | Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides |
title_short | Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides |
title_sort | heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides |
topic | Insight into Disease Pathogenesis or Mechanism of Therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685488/ https://www.ncbi.nlm.nih.gov/pubmed/26693280 http://dx.doi.org/10.1530/EDM-15-0105 |
work_keys_str_mv | AT challisbenjaming heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides AT albrechtsennicolaijwewer heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides AT bansiyavishakha heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides AT burlingkeith heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides AT barkerpeter heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides AT hartmannbolette heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides AT gribblefiona heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides AT orahillystephen heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides AT holstjensj heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides AT simpsonhelenl heterogeneityofglucagonomasduetodifferentialprocessingofproglucagonderivedpeptides |